| Objective: In this study, we investigated whether patients with LC had an imbalance in production of IL-10 and IL-12. The aim was to evaluate the cellular immune state, to provide some justification for IL-12 therapy in the fields of LC, and to estimate the role of IL-10 and IL-12 in evaluating prognosis. Methods: AM and PBMC were obtained from 35 patients with LC, 23 patients with BPD, and 6 NC. PBMC were obtained from 41 advanced NSCLC before and after systemic chemotherapy. IL-10 and IL-12 in the culture supernatants were measured quantitatively by ELISA.Results: (1) Elevated levels of IL-10 were found in LC group with respect to NC and BPD. IL-12 showed significantly lower levels than thatin BPD. (2) The levels of IL-10 had negative correlation with that of IL-12 in LC group. (3) The levels of IL-10 in LC group of stage III, IV were significantly higher than that of stage I～II. The levels of IL-12 in LC group of stage IV were significantly lower than that of stage I～II. (4) Elevated levels of IL-10 were found in SCLC group with respect to NSCLC. IL-12 from PBMC and AM were lower than that of adenocarcinoma, adenocarcinoma and squamous carcinoma separately. (5) A significant decrease of IL-10 production was observed in responders at the end of therapy, whereas values of non-responders were increased. We drew a reverse result about IL-12 production. IL-10 basal levels of responders were lower than that of non-responders. However, responders had higher basal levels of IL-12 compared with that of non-responders. Conclusions: (1) Results suggest the defect of cell-mediated immunity function presents both in local and general immune response in LC patients. (2) The higher level of IL-10 and lower level of IL-12 may serve as markers of poor prognosis. (3) The patients with LC who have impaired IL-12 and enhanced IL-10 may well benefit from BRM therapy. Our studies underlie the utilizing of IL-12 in the fields of LC in the future.
|
PDF Full Text Request